Exelixis, Inc. (EXEL) Stock Analysis 2026

HealthcareBiotechnology
$66.20
as of 2026-10-29
+43.9% (52-week)50D MA $54.66  |  200D MA $47.40

BriMind AI Score

Proprietary
46
Neutral
Price CAGR
19.2%
1Y Return
+66.7%
Analyst Upside
-16.8%
Rev Growth
10.6%

Score based on historical price CAGR, revenue growth, analyst upside, and valuation factors. Updated daily.

BriMind 1-Year Price Target

$67.24+1.6% potential
Bear Case
$43.73
Bull Case
$83.00
Model Confidence90%

An even blend of the BriMind AI model's DCF and momentum target ($74.70) and Wall Street's consensus target ($59.79).

AI scores and price targets are for informational and educational purposes only. They do not constitute financial advice or a recommendation to buy or sell any security. Past performance is not indicative of future results. Always conduct your own research before making investment decisions. Full Disclaimer →

EXEL Revenue & Profitability Breakdown

This chart shows how EXEL's revenue flows through to profit. Each row deducts a layer of costs: first the direct cost of making products/services (Cost of Revenue), then operating expenses like marketing and R&D, then taxes. What remains at the bottom is net income — the actual profit shareholders own. High gross and net margins indicate a business with strong pricing power and efficiency.

Revenue
$2.44B
Cost of Revenue
-$85.7M
Gross Profit
$2.35B96.5% margin
Operating Expenses
-$1.39B
Operating Income
$962.5M39.5% margin
Tax & Other
-$101.9M
Net Income
$860.6M35.3% margin
Gross Margin
96.5%
Operating Margin
39.5%
Net Margin
35.3%

Key Financial Metrics

Exelixis, Inc. trades at a trailing P/E of 18.15x, generates $739.7M in free cash flow, runs a debt/equity ratio of 9.00, and converts shareholder equity into profit at a 44.4% return on equity. For context: P/E ratio measures how much you pay for $1 of earnings (lower = cheaper, but fast-growing companies command higher P/E); Free Cash Flow is the cash left after running the business; Debt/Equity shows how leveraged a company is; Return on Equity shows how efficiently it turns shareholder capital into profit.

Market Cap
$14.30B
P/E (Trailing)
18.15
P/E (Forward)
13.54
PEG Ratio
2.56
Price / Book
7.79
Revenue
$2.44B
Revenue Growth
10.6%
Earnings Growth
26.2%
EPS (Trailing)
$3.18
EPS (Forward)
$4.26
Gross Margin
96.5%
Operating Margin
39.5%
Net Margin
35.3%
Return on Equity
44.4%
Return on Assets
24.0%
Free Cash Flow
$739.7M
Debt / Equity
9.00
Current Ratio
3.46
Quick Ratio
3.24
Beta
0.42
Dividend Yield
None
Payout Ratio
0.0%
Insider Ownership
1.8%
Inst. Ownership
107.2%
Short % Float
15.5%
Book Value / Share
$7.41

Wall Street Analyst Consensus

Wall Street analysts covering Exelixis, Inc. currently haven't converged on a clear consensus rating, with a mean 12-month price target of $53.69 (-18.9% vs the current price). Analysts set these targets after researching a company's earnings, competitive position, and industry trends — Strong Buy / Buy means the majority expect meaningful upside, while Hold means fair value near the current price rather than a sell signal.

Mean Target$53.69-18.9% upside

Intrinsic Value Estimates for EXEL

We use 3 valuation models to estimate EXEL's intrinsic value. Intrinsic value is what a stock is truly worth based on the company's fundamentals, independent of what the market prices it at today. If multiple models agree the stock is undervalued, that convergence is a stronger signal.

Graham Number
$23.02
-65.2% vs current
Benjamin Graham's formula: √(22.5 × EPS × Book Value). A conservative floor value for stable, profitable companies. Works best for value-oriented businesses.
P/E Based (15× trailing)
$47.70
-27.9% vs current
Multiplies trailing 12-month earnings per share by 15× — a historically average P/E for the stock market. Simple but ignores future growth.
P/E Based (15× forward)
$63.91
-3.5% vs current
Multiplies next year's estimated earnings per share by 15×. More forward-looking; useful for high-growth companies where current earnings understate potential.
Fair Value Range
$23.02 – $63.91
Average Estimate
$44.88
Potential Downside
-32.2%

Intrinsic value estimates use simplified models (Graham, DCF, P/E) and conservative assumptions. They should be used as one input among many — not as sole buy/sell guidance. For advanced analysis, see the full platform.

Technical Price Signals

EXEL is currently in a golden cross pattern, trading above its 50-day average of $54.66 and above its 200-day average of $47.40. Moving averages smooth out day-to-day volatility to reveal the underlying trend — a Golden Cross (50MA crosses above 200MA) is a classic bullish signal, a Death Cross is bearish, though both are lagging indicators that confirm trends rather than predict them.

Current Price
$66.20
50-Day MA
$54.66
▲ Price above
200-Day MA
$47.40
▲ Price above
Golden Cross Pattern
Price above both MAs — bullish signal

Compare EXEL with Peers

EXEL vs INCYExelixis vs Incyte Corporation — Which Mid-Cap Oncology

Further Reading

Research and guides that put EXEL’s numbers in context — how to read the filings behind them, and the frameworks we use to score them.

Risk ManagementHow to Build Your First Investment Portfolio: Risk Tolerance, Asset Allocation & Your First 5 FundsFundamentalsWarren Buffett Retired 2026: Berkshire Portfolio Under Greg AbelBeginnerWhat Is an AI Stock Score? How BriMindInvest Ranks StocksMarket TheoryStock Market Seasonality: Monthly Returns, 'Sell in May,' and What History Says

More Healthcare Stock Analysis

In-depth reports on companies operating alongside EXEL — business models, bull and bear cases, and the metrics that matter.

CRSPCRISPR Therapeutics AGBiotechnologyPRMEPrime Medicine, Inc.BiotechnologyALNYAlnylam Pharmaceuticals, Inc.BiotechnologyCORTCorcept Therapeutics IncorporatedBiotechnologyNTLAIntellia Therapeutics, Inc.BiotechnologyRXRXRecursion Pharmaceuticals, Inc.BiotechnologyVRTXVertex Pharmaceuticals IncorporatedBiotechnologyINSMInsmed IncorporatedBiotechnology

Unlock the Full EXEL Analysis

Interactive price charts, real-time AI signals, advanced DCF models, portfolio tracking, earnings analysis, and side-by-side peer comparisons. Start your 14-day free trial — no credit card required.

Start Free TrialBrowse All Stocks
Data sources: Financial metrics and market data sourced from company SEC filings, earnings releases, and investor relations disclosures. Price data, analyst consensus targets, and fundamental financials provided by financial market data providers. ETF data sourced from official fund prospectuses and index provider publications. AI scores and price targets are proprietary estimates — see our Methodology and Disclaimer for details.
← Back to Home · Browse All Stock Analysis